Shanghai has quietly vaulted to the front line of a technology long confined to the laboratory: clinical brain‑computer interfaces (BCIs). In a milestone for the field, a local company, BoruiKang (博睿康), won what Chinese regulators describe as the world’s first Class‑III medical device registration for an implantable invasive BCI — NEO — clearing the way for regulated clinical use of a product that had previously only been tested in trials.
NEO’s approval follows a program of clinical work including 36 implants spanning feasibility and multicentre confirmatory trials, with trial endpoints reported as of November 2025. Patients in the studies showed measurable improvements in hand‑grip function and, in some cases, signs of neural remodelling. BoruiKang plans to prioritise roll‑out at tertiary hospitals that took part in its trials and is already pursuing a listing on China’s STAR Market, highlighting the close linkage between clinical validation and capital markets in China’s innovation ecosystem.
BoruiKang is not an isolated success. Shanghai now hosts roughly 60 BCI companies covering invasive, semi‑invasive and non‑invasive technologies, creating a full‑stack industrial ecology that spans component manufacturing, algorithm development, clinical translation and commercial deployment. Another local firm, Jiedi Medical (阶梯医疗), has raised large strategic capital rounds led by Alibaba and announced the clinical implantation of a 256‑channel wireless invasive system (WRS02) — a device that its backers expect could be a major step up in channel count and throughput and is already in the regulator’s ‘‘green channel’’ for innovative devices.
The city’s cluster includes niche technical breakthroughs: a team known as BrainTiger (脑虎科技) has completed a prospective clinical trial decoding Mandarin in real time, a notable achievement because tonal languages are more challenging to decode than alphabetic languages. Other start‑ups have translated local academic work into products for stroke rehabilitation, depression screening and sleep diagnostics, while one company’s brain‑spinal interface has entered the U.S. Food and Drug Administration’s Breakthrough Device pathway.
Shanghai’s lead is not accidental. The city combines deep biomedical, semiconductor and AI talent pools with top‑tier hospitals — from Fudan University and Huashan Hospital to Shanghai Jiao Tong University — that can host and validate early clinical work. The municipal government has actively shaped the environment with infrastructure such as a dedicated ‘‘Brain Intelligence’’ industrial park, local industry standards and a 2025–2030 action plan focused on bringing invasive and semi‑invasive products to market. At the national level, the 2026 government work plan elevated BCIs alongside quantum, embodied intelligence and 6G as strategic future industries, lending political priority to the sector.
This alignment of talent, clinical capacity, capital and policy is catalysing a rapid commercialisation wave, but it also raises thorny questions. Implantable BCIs carry long‑term safety, regulatory and ethical burdens: device durability, infection risks, neural tissue response and privacy of neural data remain unsettled. The commercial drive — evident in aggressive fundraising, IPO preparations and plans for large multicentre registries — risks outpacing the slow, cautious work needed to understand long‑term outcomes.
Internationally, China’s progress will alter the competitive map. U.S. firms such as Neuralink have dominated headlines, but Shanghai’s mix of rapid clinical testing, state support and integrated industrial supply chains could close the gap on channel count, trial scale and commercial availability. That will complicate global collaboration and export strategies, and it will shine a spotlight on governance: how regulators, hospitals and companies manage patient expectations, data governance and cross‑border research will determine whether China’s early lead translates into long‑term, responsible leadership in neurotechnology.